- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00118235
Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer
Cisplatin, Irinotecan and Bevacizumab (NSC# 704865) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase II Study
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To determine the percentage of patients with extensive stage small cell lung cancer treated with cisplatin, irinotecan and bevacizumab who live longer than 12 months.
SECONDARY OBJECTIVES:
I. To assess the response rate of patients treated with cisplatin, irinotecan and bevacizumab.
II. To evaluate the toxicity and tolerability of the combination of cisplatin, irinotecan and bevacizumab.
III. To determine the association between VEGF/KDR complex expression and VEGF plasma levels and tumor response.
OUTLINE:
Patients receive cisplatin IV over 60 minutes and irinotecan IV over 90 minutes on days 1 and 8. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 3 years.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60606
- Cancer and Leukemia Group B
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02903
- Rhode Island Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- All patients must have histologically or cytologically documented small cell carcinoma of the bronchus
- The extensive disease classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive stage patients are defined as those patients with extrathoracic metastases, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathy or contralateral hilar adenopathy
- Measurable or Non-measurable Disease
- No prior chemotherapy or investigational therapy for SCLC
- Radiation therapy must have been completed at least three weeks before initiation of protocol therapy
- No major surgical procedure within 28 days prior to starting treatment and fully recovered
- No minor surgical procedure (mediastinoscopy or core biopsy) within 7 days prior to starting treatment
- ECOG performance status: 0-2
- No "currently active" second malignancy other than non-melanoma skin cancers
- No CNS metastases; patients with a history of CNS metastases will NOT be eligible even if they have completed a course of CNS radiotherapy; all patients will have a screening brain CT or MRI to rule out occult CNS metastases
- No recent history of CVA (within 6 months)
- No serious or non-healing wound ulcer or bone fracture
- Patients with a history of significant bleeding episodes (e.g., hemoptysis, bleeding diathesis, upper or lower GI bleeding) are not eligible; patients with trace blood in the sputum ("blood tinged sputum") are eligible
- No myocardial infarction or significant change in anginal pattern within one year or current congestive heart failure (NYHA Class 2 or higher)
- Patients with a history of hypertension must be well controlled (< 150/90) on a stable regimen of anti-hypertensive therapy
- No HIV-positive patients receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with the protocol treatment; (patients with immune deficiency are at an increased risk of lethal infections when treated with marrow-suppressive therapy)
- No chronic daily treatment with aspirin (> 325 mg/day) or on non-steroidal antiinflammatory agents known to inhibit platelet function; no treatment with dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix), cilostazol (Pletal), or other antiplatelet agents
- No clinically significant peripheral neuropathy (grade >= 2)
- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
- No treatment with therapeutic anticoagulation; prophylactic anticoagulation for central venous access devices is allowed provided requirements of INR < 1.5 and PTT < 1.2 x ULN are met; caution should be taken in treating patients with low dose heparin or low molecular weight heparin for DVT prophylaxis as there may be an increased bleeding risk with bevacizumab
- No current and/or recent (within 1 month) use of a thrombolytic agent; low dose thrombolytic therapy for maintenance of central venous catheter is allowed
- No clinically significant peripheral arterial disease
- Non-pregnant and non-nursing; the effect of the combination of bevacizumab, cisplatin, and irinotecan on the fetus and infant is unknown
- Granulocytes >= 1,500/μl
- Platelets >= 100,000/μl
- Serum Creatinine =< ULN
- Total Bilirubin < 2.0 mg/dl
- SGOT < 2 x ULN
- INR < 1.5
- PTT < 1.2 x ULN
- Urine protein (dipstick) < 1+
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Treatment (cisplatin, irinotecan hydrochloride, bevacizumab)
Patients receive cisplatin IV over 60 minutes and irinotecan IV over 90 minutes on days 1 and 8. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
|
Korrelative undersøgelser
Givet IV
Andre navne:
Givet IV
Andre navne:
Givet IV
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Survival time
Tidsramme: The time beginning at randomization until death or last known follow-up, assessed up to 4 years
|
Described using Kaplan-Meier curves.
|
The time beginning at randomization until death or last known follow-up, assessed up to 4 years
|
|
Failure-free survival
Tidsramme: The time between randomization and the occurrence of disease progression, or death, whichever comes first, assessed up to 4 years
|
Described using Kaplan-Meier curves.
|
The time between randomization and the occurrence of disease progression, or death, whichever comes first, assessed up to 4 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency of toxicity, tabulated by the most severe occurrence
Tidsramme: Up to 4 years
|
Graded using the NCI CTCAE version 3.0.
|
Up to 4 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Neal Ready, Cancer and Leukemia Group B
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Luftvejssygdomme
- Neoplasmer
- Lungesygdomme
- Neoplasmer efter sted
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Småcellet lungekarcinom
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antineoplastiske midler
- Immunologiske faktorer
- Topoisomerasehæmmere
- Angiogenese-hæmmere
- Angiogenesemodulerende midler
- Vækststoffer
- Væksthæmmere
- Topoisomerase I-hæmmere
- Antistoffer
- Cisplatin
- Immunoglobuliner
- Bevacizumab
- Irinotecan
- Antistoffer, monoklonale
- Antineoplastiske midler, immunologiske
Andre undersøgelses-id-numre
- NCI-2012-02815 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U10CA031946 (U.S. NIH-bevilling/kontrakt)
- P30CA014236 (U.S. NIH-bevilling/kontrakt)
- CDR0000433341
- CALGB-30306 (Anden identifikator: CTEP)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .